Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer

|

|

Summary

This summary is machine-generated.

Post-operative stimulated thyroglobulin levels are effective predictors of differentiated thyroid cancer treatment success. A stimulated thyroglobulin level below 1 ng/mL suggests radioiodine therapy may not be beneficial.

Area Of Science

  • Endocrinology
  • Nuclear Medicine
  • Oncology

Background

  • Serum thyroglobulin (Tg) monitoring is crucial for differentiated thyroid cancer (DTC) management post-thyroidectomy and radioiodine therapy.
  • Predictive biomarkers can identify patients at risk of recurrence or treatment failure.

Purpose Of The Study

  • To compare the predictive value of post-operative stimulated thyroglobulin (sTg) levels and absorbed dose to the thyroid remnant for radioiodine therapy success in DTC.
  • To identify patients who may not benefit from radioiodine therapy.

Main Methods

  • Observational clinical studies (MEDIRAD) in France, Germany, and the UK.
  • Recruitment of DTC patients treated with 1.1 or 3.7 GBq radioiodine under recombinant human thyrotropin (rhTSH) stimulation or thyroid hormone withdrawal.
  • Determination of maximum absorbed dose to the thyroid remnant and comparison with post-operative sTg for predicting ablation success.

Main Results

  • Ninety-four patients with negative antithyroglobulin antibodies were analyzed.
  • Post-operative sTg levels demonstrated strong predictive power for ablation success (ROC AUC 0.83 ± 0.05).
  • A dose-response relationship was observed between absorbed dose and ablation success in patients with sTg ≥1 ng/mL.

Conclusions

  • Post-operative sTg and absorbed dose can guide personalized management of DTC.
  • Patients with post-operative sTg <1 ng/mL are unlikely to benefit from radioiodine therapy.
  • These biomarkers help identify patients requiring further treatment or intensified follow-up.